Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.

BMC medical genomics - 26 Mar 2026

Pilon Marc-Olivier, de Denus Simon, Asselin Géraldine, Legault Marc-André, Ngongang Kwandjang Hervira Brenda, Barhdadi Amina, Lemieux Perreault Louis-Philippe, Valois Diane, Mongrain Ian, Haefliger Carolina, Paul Dirk S, Pearson Ewan R, Tardif Jean-Claude, Dubé Marie-Pierre

Abstract excerpt

BACKGROUND: Saxagliptin is a DPP-4 inhibitor widely used to manage type 2 diabetes, though genetic contributors to variability in response remain unclear. This study aimed to identify genetic variants associated with the efficacy and safety of saxagliptin using genome-wide association studies (GWAS) with data from randomized controlled trials. METHODS: GWAS were conducted on glycated hemoglobin (HbA1c) levels and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus, Type 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dipeptides

Share to Genome-Wide Association Study

Share to Glycated Hemoglobin

Share to Hypoglycemia

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 41882721
DOI: 10.1186/s12920-026-02348-z
PMCID: PMC13147865

Genes

CCSER2
KDM7A
OGFOD3
TBC1D3D
TYSND1
UBE2E1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events.PMID 41882721Read ↗

Heterogeneous effect of saxagliptin on glucose fluctuation and β-cell function in T1DM: a multicentre, randomised trial.Semantic proximity Read ↗

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to SulfonylureasSemantic proximity Read ↗

Pharmacogenomic Profiling of Selected Genes Influencing Anti-Diabetic Drug Response in the Pakistani Pashtun Population: Shifting from Trial-and-Error to Precision MedicineSemantic proximity Read ↗

Polygenic Susceptibility to Diabetes and Poor Glycemic Control in Stroke SurvivorsSemantic proximity Read ↗

A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas.Semantic proximity Read ↗

KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Semantic proximity Read ↗

Genetic Predictors of Response to Oral Insulin for Type 1 Diabetes Prevention.Semantic proximity Read ↗

Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.Semantic proximity Read ↗

AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects.Semantic proximity Read ↗

Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease.Semantic proximity Read ↗

Convergent human genetic evidence implicates serine biosynthesis in diabetic peripheral neuropathySemantic proximity Read ↗

Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.